Pharma BD Deal Intelligence
GSK's $57M bet on Genelabs' HCV chemistry never produced a marketed drug — GSK divested the lead compound to Janssen in 2013, which also never launched it, and the entire program was overtaken by Gilead's Sovaldi/Harvoni revolution.
Full analysis, sources & comparables →GSK announced the acquisition to strengthen its focus on novel small-molecule therapies for hepatitis C, leveraging Genelabs' partnered and proprietary…
Genelabs board unanimously determined the tender offer fair and in shareholders' best interests; transaction conditioned on 90% acceptance, supported by Cowen…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$1.30/share tender; Hepatitis C novel small molecule programs; tender completed Jan 2009
GSK's $57M bet on Genelabs' HCV chemistry never produced a marketed drug — GSK divested the lead compound to Janssen in 2013, which also never launched it, and the entire program was overtaken by Gilead's Sovaldi/Harvoni revolution.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Genelabs Technologies, Inc. (this deal) | 2008 | $57M | 21 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2008 deals · GlaxoSmithKline plc deals